Australian Dementia Network Limited
The Australian Dementia Network Limited (ADNeT Ltd, or ADNL) was established on 19 February 2020 as a not-for-profit company limited by guarantee to support the Australian Dementia Network (ADNeT) in achieving its strategic objective of furthering dementia research efforts across Australia.
ADNeT Ltd supports the network by:
- generating additional income (particularly from industry for screening and trials activities, and potentially from states or philanthropic sources), and
- more generally, coordinating dementia research funding and development throughout Australia.
Establish an integrated network of dementia researchers, clinicians, service providers, industry, and consumers to drive this priority national translational research initiative;
Develop and maintain a clinical quality registry that can track, benchmark and report on the quality of clinical care of people with dementia and mild cognitive impairment to drive quality improvement, identify suitable and willing persons for clinical trials, and systematically collect longitudinal data for research on the determinants, epidemiology and trajectory of cognitive decline;
Establish a national network of memory clinics to optimise the assessment of cognitive disorders and improve specialist access for all Australians;
Develop a large, highly characterised cohort of people with dementia, or at increased risk of dementia, to populate a trials-ready cohort for participation in cutting-edge clinical trials and to study the natural history of dementia;
Connect with existing infrastructure supporting clinical trials in Australia to enhance the capacity for state-of-the-art assessments and the conduct of clinical trials nationwide; and
Integrate Australian research with the international effort to prevent or effectively treat dementia.
ADNeT Ltd has built and continuously strengthened partnerships with leading pharmaceutical organisations in the world as well as the Australian Government. Notable collaborative engagements over the past few years include:
- Development of the ADNeT Registry Clinical Research Platform (CRP).
- Recruiting and screening participants for various studies (AHEAD, EVOKE, Clarity amongst others) and referring suitable amyloid positive subjects to trial sites.
- Conducting national survey of health professional experts within the ADNeT Memory Clinic network to characterise current clinical landscape in order to offer disease modifying therapies to eligible patients.
- Genotyping for variants of TREM2.
ADNeT Ltd is registered with the Australian Charities and Not-for-Profits Commission as a charitable organisation.
Board of Directors
Professor Graeme Samuel AC – Chairman
Chair, Dementia Australia
Independent Reviewer of the Commonwealth Government’s Environment Laws
Former Chair of ACCC
Former Chair of NNIDR
Professor Christopher Rowe BMBS, FRACP, MD, FAANMS
Director, Australian Dementia Network, University of Melbourne.
Director, Molecular Imaging Research, Austin Health.
NHMRC Practitioner Fellow
Highly Cited Researcher 2019 (Top 1% in Neuroscience)
Professor Peter Schofield
CEO, Neuroscience Research Australia (NeuRA)
Professor, School of Medical Sciences, University of NSW
Founder and Principal of Lahra Carey Media & Communications
Director, Foodbank Victoria
Former partner KPMG Head of Mergers & Acquisitions and Head of Private Equity for KPMG Corporate Finance
Executive Chairman, Axsia Pty Ltd
Former Vice President & General Manager Australia/New Zealand AbbVie
Chairman, Australian Alzheimer’s Research Foundation
CEO, Hall and Prior Residential Health and Aged Care Group
Dr Alison Roberts
CEO, Airlines for Australia and New Zealand
Dr Priscilla Rogers, PhD
Director, Upstart Innovations